Operating cash flow was negative in all ten reported quarters, with free cash flow ranging from negative $71.6 million in 2024Q2 to negative $39.5 million in 2026Q3, and capital expenditures remaining minimal, indicating the burn tracks operating losses.
Sana Biotechnology, Inc. (SANA) cash flow statement — 8-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Cash from Operations | -141.56M | -143.83M | -223.15M | -253.58M | -290.05M | -251.05M | -137.98M | -85.5M | -13.49M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 23.23% | 35.55% | 12% | 12.57% | -15.53% | -81.95% | -61.37% | -533.6% | - |
| Net Income | -149.27M | -244.17M | -266.76M | -283.25M | -269.48M | -355.93M | -285.31M | -130.78M | -13.25M |
| Depreciation & Amortization | 15.71M | 12.75M | 15.5M | 24.56M | 15.63M | 11.07M | 5.92M | 1.83M | 1K |
| Stock-Based Compensation | 22.67M | 25.46M | 37.68M | 35.53M | 38.34M | 22.36M | 5.83M | 1.5M | 118K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7.55M | 0 |
| Other Non-Cash Items | -22.84M | 72.24M | -8.39M | -49.03M | -82.08M | 61.64M | 129.42M | 38.97M | -228K |
| Working Capital Changes | -7.83M | -10.11M | -1.19M | 18.61M | 7.54M | 9.8M | 6.16M | 10.53M | -308K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -35K | -3.54M | 1.38M | 1.03M | 1.06M | -266K | 1.98M | -421K | 289K |
| Cash from Investing | -32.23M | -40.24M | 17.45M | 172.01M | 210.56M | -245.8M | -252.56M | -87.86M | -780K |
| Capital Expenditures | -3.57M | -938K | -33.43M | -20.03M | -20.88M | -29.86M | -23.87M | -26.18M | -460K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 883K | 1.43M | 0 | -192.04K | -231.44K | 0 | 0 | -3.19M | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 94K | 0 | 0 | 192.04K | 231.44K | -4.57M | 0 | 59K | -320K |
| Cash from Financing | 111.1M | 128.73M | 199.75M | 31.65M | 4.91M | 631.75M | 435.69M | 223.73M | 45.72M |
| Debt Issued (Net) | -182K | -347K | 188.74M | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 111.47M | 129.08M | 192M | 31.65M | 4.91M | 631.75M | 435.54M | 223.74M | 45.72M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -184K | 0 | -181M | 0 | 0 | 0 | 149K | -14K | 0 |
| Net Change in Cash | -62.69M | -55.33M | -5.95M | -49.92M | -74.58M | 134.9M | 45.14M | 50.36M | 31.45M |
| Free Cash Flow | -145.13M | -144.77M | -256.58M | -273.61M | -310.93M | -280.92M | -161.85M | -111.69M | -13.96M |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 8.63% | 43.58% | 6.22% | 12% | -10.68% | -73.56% | -44.92% | -700.34% | - |
| FCF per Share | -0.47 | -0.57 | -1.11 | -1.41 | -1.65 | -1.69 | -0.86 | -0.60 | -0.07 |
| FCF Conversion (FCF/Net Income) | 0.97x | 0.59x | 0.84x | 0.90x | 1.08x | 0.71x | 0.48x | 0.65x | 1.02x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying SANA stock.
Sana Biotechnology, Inc. (SANA) generated $-143.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Sana Biotechnology, Inc. (SANA) reported negative free cash flow of $144.8M in 2025, indicating capital requirements exceeded cash from operations.
Sana Biotechnology, Inc. (SANA) spent $0.9M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Cash runway constraint, dilution risk
Metrics are mathematically derived from official filings.
Operating Cash Burn Persists Despite Swings
Based on reported figures, Sana's operating cash flow stayed negative in every one of the ten reported quarters, with OCF/NI ratios of 0.35 to 1.16 indicating the cash drain tracks operating losses rather than non-cash noise.
The OCF-to-net-income ratio is not meaningful in quarters with positive net income, such as 2026Q3, where a $20.4 million profit coexisted with a $38.8 million operating cash outflow, suggesting the earnings turn is driven by non-operating or non-cash items. Across the period, operating cash outflows of roughly $30 million to $58 million per quarter align closely with reported losses, which implies that the stock-based compensation add-back of about $5 to $11 million per quarter is not what is masking the burn. Investors should treat the 2026Q3 profit as a potential accounting artifact and monitor whether future quarters reconcile net income with operating cash flow.
Free Cash Flow Deficit Narrowing Unevenly
As reported in financial statements, Sana's free cash flow ranged from negative $71.6 million in 2024Q2 to negative $33.0 million in 2025Q2, with the most recent quarter at negative $39.5 million reflecting a reversal of the earlier narrowing trend.
Free cash flow has no revenue denominator, so the FCF margin is unavailable, and the trajectory must be read in absolute dollars, where the burn has oscillated rather than declined steadily. The 2026Q3 deterioration to negative $39.5 million, after several quarters in the $33 million to $38 million range, suggests spending pressure is re-accelerating as clinical programs advance. This pattern warrants attention because a sustained burn rate near $35 million to $40 million per quarter implies a runway measured in a small number of quarters against the reported $71.87 million cash balance.
Minimal Capital Intensity Limits Asset Drag
According to recent SEC filings, Sana's capital expenditures remained small, ranging from a $112,000 inflow to a $13.1 million outflow, which indicates the company is not building fixed-asset capacity at scale.
Capex/revenue cannot be computed because revenue is absent, but the dollar figures show that the bulk of the 2024Q2 $13.1 million outlay was a one-time facility or equipment commitment rather than a recurring maintenance requirement. Since capex averaged well under $1 million in most recent quarters while D&A ran between $2 million and $8 million, the depreciation base is likely dominated by previously acquired lab assets and intangibles. This suggests near-term capex is unlikely to be the primary driver of cash consumption, which remains tied to R&D operating spend.
Working Capital Swings Mask Underlying Burn
Based on Sana's reported figures, working capital changes ranged from a $10.9 million drain in 2025Q1 to a $4.3 million inflow in 2024Q4, a volatility large enough to shift quarterly cash burn by a meaningful share.
The alternating sign of working capital movements, including a $6.5 million outflow in 2026Q1 followed by a $1.5 million inflow in 2026Q2, suggests timing differences in accrued clinical and payable balances rather than a structural shift in collections or payment terms. Because there is no revenue receivable base, the swings most likely reflect accrual timing on research contracts, which may reverse and therefore should not be extrapolated. Analysts should avoid treating favorable quarters as evidence of improving efficiency given the absence of a receivables cycle to interpret.
Runway Risk Obscured by Loss Narrowing
Based on reported figures, Sana's $71.87 million cash position against quarterly operating outflows frequently exceeding $30 million suggests the balance covers only a few quarters, which may force dilutive financing before clinical milestones are reached.
The positive 2026Q3 net income could be read as improvement, yet the same quarter shows a $38.8 million operating outflow and a $39.5 million free cash deficit, so the earnings figure does not reflect liquidity generation. Cash reserves are not augmented by operations, and the reported Debt/Equity of 0.49 provides limited offset to the pressure of needing new equity or partnership capital. The cash flow data does not disclose committed financing or non-dilutive funding, so these outcomes warrant further investigation rather than being assumed.